Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 871-876

  Buesa, J M ^a   Lopez Pousa A ^b   Martin J ^c   Anton A ^d   Garcia Del Muro J ^e   Bellmunt, J ^f   Arranz, F ^a   Valenti V ^b   Escudero, P ^g   Menendez D ^b   Casado, A ^h   Poveda, A ⁱ  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

High dose ifosfamide; Soft tissue sarcomas

Indexed keywords

DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 7344222584     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008474802882     Document Type: Article

References (28)

1. Gottlieb JA, Baker LH, O'Bryan RM et al. Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 1975; 6: 271-82.
2. Verweij J, van Oosterom AT, Somers R et al. Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. Ann Oncol 1992; 3: S75-80.
3. Stuart-Harris RC, Harper PG, Parsons CA et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1983; 11: 69-72.
4. Bramwell VHC, Mouridsen HT, Santoro A et al. Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987; 23: 311-21.
5. Antman KH, Ryan L, Elias A et al. Response to ifosfamide and mesna: One hundred twenty-four previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 126-31.
6. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30: 725-32.
7. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33: 36-42.
8. Lind MJ, Margison JM, Cerny T et al. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989; 49: 753-7.
9. Klein HO, Wickramanayake PD, Christian E, Coerper C. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asia Z 7557). Cancer 1984; 54: 1193-203.
10. Elias AD, Eder JP, Shea T et al. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990; 8: 170-8.
11. Cerny T, Leyvraz S, Dazzi H et al. Phase II trials of ifosfamide and mesna in advanced soft tisuue sarcoma patients: A definite dose-response relationship. Proc Am Soc Clin Oncol 1992; 11:416 (Abstr).
12. Brain E, Le Cesne A, Le Chevalier Tet al. High dose ifosfamide can circumvent resistance to standard dose ifosfamide in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1993; 12: 470 (Abstr).
13. Buesa JM, Sanz A, Arranz F et al. Ifosfamida a dosis altas en pacientes con sarcoma de partes blandas previamente tratados con quimioterapia. Oncologia 1995; 18: 97 (Abstr).
14. Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: Uniform response of metastases to high-dose ifosfamide. Cancer 1994; 73: 2506-11.
15. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
16. Kupfer A, Aeschlimann C, Wermuth B et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343: 763-4.
17. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
18. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies, dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
19. Schütte J, Kellner R, Seeber S. Ifosfamide in the treatment of soft-tissue sarcomas: Experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol 1993; 31: S184-98.
20. Palumbo R, Palmeri S, Antimi M et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997; 8: 1159-62.
21. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M. D. Anderson experience. Cancer Chemother Pharmacol 1993; 31: S174-9.
22. Toma S, Palumbo R, Comandone A et al. Ambulatory four-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: A phase I study. Ann Oncol 1995; 6: 193-6.
23. Cervellino JC, Araujo CE, Pirisi C et al. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: A GETLAC study. Cancer Chemother Pharmacol 1990; 26: S1-3.
24. Bellmunt J, Eres N, Ribas A et al. Feasibility trial of high-dose seven-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol 1997; 40: 273-6.
25. Chawla SP, Rosen G, Lowenbraun S et al. Role of high dose ifosfamide in recurrent osteosarcoma. Proc Am Soc Clin Oncol 1990; 9: 310 (Abstr).
26. Brade WP, Herdrich K, Kachel-Fischer U , Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117: S164-86.
27. Cerny T, Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992; 3: 679-81 (Editorial).
28. Cerny T, Castiglione M, Brunner K et al. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990; 335: 175 (Letter).